Literature DB >> 26354814

Usefulness of Adjunctive Fecal Calprotectin and Serum Procalcitonin in Individuals Positive for Clostridium difficile Toxin Gene by PCR Assay.

Kristin Y Popiel1, Romina Gheorghe2, Jennifer Eastmond2, Mark A Miller2.   

Abstract

In 54/64 subjects with nosocomial diarrhea, fecal calprotectin levels correlated with the results of stool samples tested for Clostridium difficile toxin gene by PCR. Fecal calprotectin levels can be used as an adjunctive measure to PCR to support the diagnosis of C. difficile infection.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26354814      PMCID： PMC4609681          DOI： 10.1128/JCM.02230-15

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  10 in total

1.  Impact of the type of diagnostic assay on Clostridium difficile infection and complication rates in a mandatory reporting program.

Authors:  Yves Longtin; Sylvie Trottier; Gilles Brochu; Bianka Paquet-Bolduc; Christophe Garenc; Vilayvong Loungnarath; Catherine Beaulieu; Danielle Goulet; Jean Longtin
Journal:  Clin Infect Dis       Date:  2012-09-25       Impact factor: 9.079

2.  Clinical characteristics and outcome of patients with Clostridium difficile infection diagnosed by PCR versus a three-step algorithm.

Authors:  C Beaulieu; L-L Dionne; A-S Julien; Y Longtin
Journal:  Clin Microbiol Infect       Date:  2014-07-12       Impact factor: 8.067

3.  Is there any value in measuring faecal calprotectin in Clostridium difficile positive faecal samples?

Authors:  Simon J Whitehead; Kate E Shipman; Mike Cooper; Clare Ford; Rousseau Gama
Journal:  J Med Microbiol       Date:  2014-01-25       Impact factor: 2.472

4.  Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea.

Authors:  Yogesh M Shastri; Dominik Bergis; Nada Povse; Volker Schäfer; Sarika Shastri; Martin Weindel; Hans Ackermann; Jürgen Stein
Journal:  Am J Med       Date:  2008-12       Impact factor: 4.965

Review 5.  The efficacy of procalcitonin as a biomarker in the management of sepsis: slaying dragons or tilting at windmills?

Authors:  Prasanna Sridharan; Ronald S Chamberlain
Journal:  Surg Infect (Larchmt)       Date:  2013-11-25       Impact factor: 2.150

6.  Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection.

Authors:  Timothy D Planche; Kerrie A Davies; Pietro G Coen; John M Finney; Irene M Monahan; Kirsti A Morris; Lily O'Connor; Sarah J Oakley; Cassie F Pope; Mike W Wren; Nandini P Shetty; Derrick W Crook; Mark H Wilcox
Journal:  Lancet Infect Dis       Date:  2013-09-03       Impact factor: 25.071

7.  Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply?

Authors:  A Dhaliwal; Z Zeino; C Tomkins; M Cheung; C Nwokolo; S Smith; C Harmston; R P Arasaradnam
Journal:  Frontline Gastroenterol       Date:  2014-03-17

8.  Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy.

Authors:  Mark A Miller; Thomas Louie; Kathleen Mullane; Karl Weiss; Arnold Lentnek; Yoav Golan; Yin Kean; Pam Sears
Journal:  BMC Infect Dis       Date:  2013-03-25       Impact factor: 3.090

9.  Procalcitonin levels associate with severity of Clostridium difficile infection.

Authors:  Krishna Rao; Seth T Walk; Dejan Micic; Elizabeth Chenoweth; Lili Deng; Andrzej T Galecki; Ruchika Jain; Itishree Trivedi; Marie Yu; Kavitha Santhosh; Cathrin Ring; Vincent B Young; Gary B Huffnagle; David M Aronoff
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240

10.  Calprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): a prospective cohort study.

Authors:  Andrew Swale; Fabio Miyajima; Paul Roberts; Amanda Hall; Margaret Little; Mike B J Beadsworth; Nick J Beeching; Ruwanthi Kolamunnage-Dona; Chris M Parry; Munir Pirmohamed
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240
  10 in total
  4 in total

1.  Faecal lactoferrin and calprotectin in patients with Clostridium difficile infection: a case-control study.

Authors:  F Barbut; C Gouot; N Lapidus; L Suzon; R Syed-Zaidi; V Lalande; C Eckert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-08-12       Impact factor: 3.267

Review 2.  Laboratory Tests for the Diagnosis of Clostridium difficile.

Authors:  Karen C Carroll; Masako Mizusawa
Journal:  Clin Colon Rectal Surg       Date:  2020-02-25

3.  Fecal calprotectin concentrations in cancer patients with Clostridium difficile infection.

Authors:  Taojun He; Samuel E Kaplan; Luz A Gomez; Xuedong Lu; Lakshmi V Ramanathan; Mini Kamboj; Yi-Wei Tang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-09-21       Impact factor: 3.267

Review 4.  Current knowledge on the laboratory diagnosis of Clostridium difficile infection.

Authors:  Adrián Martínez-Meléndez; Adrián Camacho-Ortiz; Rayo Morfin-Otero; Héctor Jesús Maldonado-Garza; Licet Villarreal-Treviño; Elvira Garza-González
Journal:  World J Gastroenterol       Date:  2017-03-07       Impact factor: 5.742
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.